Apollo Medical Holdings, Inc. (AMEH)
(Delayed Data from NSDQ)
$19.93 USD
+0.41 (2.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.93 USD
+0.41 (2.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Apollo Medical Holdings, Inc. (AMEH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) closed the most recent trading day at $29.59, moving -0.44% from the previous trading session.
Is the Options Market Predicting a Spike in Apollo Medical (AMEH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Apollo Medical (AMEH) stock based on the movements in the options market lately.
New Strong Buy Stocks for November 22nd
by Zacks Equity Research
DCBO, APPF, AMEH, FUTU and ZEUS have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2022.
Premier, Inc. (PINC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of -8.77% and 4.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Q4 Loss Narrows on Higher Visits, Memberships
by Zacks Equity Research
Teladoc (TDOC) projects 2022 total visits in the band of 18.5-20 million, indicating an uptick from the 2021 level of 15.4 million.
New Strong Buy Stocks for February 4th
by Zacks Equity Research
ARCB, UMC, UTI, AMN, and AMEH have been added to the Zacks Rank #1 (Strong Buy) List on February 4, 2022.
Zacks Industry Outlook Highlights: AMN Healthcare Services, Apollo Medical Holdings, Inc. and LifeMD, Inc
by Zacks Equity Research
AMN Healthcare Services, Apollo Medical Holdings, Inc. and LifeMD, Inc are highlighted in this Industry Outlook article.
Zacks Industry Outlook Highlights: AMN Healthcare Services, Apollo Medical Holdings, Inc and LifeMD, Inc
by Zacks Equity Research
AMN Healthcare Services, Apollo Medical Holdings, Inc and LifeMD, Inc are highlighted in this industry outlook article.
3 Medical Services Stocks to Buy Despite Near-Term Industry Woes
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. AMN, AMEH and LFMD are set to gain the most. However, falling healthcare spending may disrupt the trend.
MODV vs. AMEH: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. AMEH: Which Stock Is the Better Value Option?
MODV or AMEH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MODV vs. AMEH: Which Stock Is the Better Value Option?
MODV vs. AMEH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MODV vs. AMEH: Which Stock Is the Better Value Option?
AMN vs. AMEH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. AMEH: Which Stock Is the Better Value Option?
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
Zacks.com featured highlights include: Vista Outdoor, Canon, Apollo Medical, Tyler Tech and ResMed
by Zacks Equity Research
Zacks.com featured highlights include: Vista Outdoor, Canon, Apollo Medical, Tyler Tech and ResMed
Betting on These 5 Low-Beta Stocks is Ideal in a Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. VSTO, CAJ, AMEH, TYL and RMD are the frontrunners.
3 Momentum Anomaly Stocks to Create a Winning Portfolio
by Zacks Equity Research
Skechers (SKX), OneMain Holdings (OMF) and Apollo Medical (AMEH) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Here's Why You Should Invest In Globus Medical (GMED) Now
by Zacks Equity Research
Strong first-quarter performance by the U.S. Spine and Enabling Technologies business contributed to Globus Medical's (GMED) top line.
Zacks.com featured highlights include: Apollo Medical, Hibbett, Controladora Vuela Compania de Aviacion, Nike and Lands' End
by Zacks Equity Research
Zacks.com featured highlights include: Apollo Medical, Hibbett, Controladora Vuela Compania de Aviacion, Nike and Lands' End
5 Stocks With Recent Price Strength Amid Recent Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Stocks seeing price strength like NKE, VLRS, LE, AMEH and HIBB have a high chance of carrying the momentum forward.
Here's Why You Should Add Teleflex (TFX) to Your Portfolio
by Zacks Equity Research
Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).
Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS
by Zacks Equity Research
Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.
National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes
by Zacks Equity Research
National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
by Zacks Equity Research
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
Here's Why You Should Retain Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.